Effectiveness of Speech Therapy for Lip-reading in Patients With Hearing Aids: SCED Study (NCT07028658) | Clinical Trial Compass
RecruitingNot Applicable
Effectiveness of Speech Therapy for Lip-reading in Patients With Hearing Aids: SCED Study
France8 participantsStarted 2025-10-16
Plain-language summary
This study aims to investigate whether lip reading rehabilitation improves viseme recognition in individuals with hearing impairments who use hearing aids.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient aged 18 or older
* Affiliated with a social security system
* Moderate to severe bilateral post-lingual hearing loss, fitted with hearing aids for more than 6 months
* Wearing hearing aids for a minimum of 8 hours/day on average over the past month
* Intelligibility in quiet \> 80% correct responses at 60 dB (Lafon cochlear list)
* Difficulty in noisy environments rated \> 6 on a 0-10 EVA scale
* French language comprehension level of at least B1 CEFR (Common European Framework of Reference for Languages)
* Willing to participate in speech therapy rehabilitation at a rate of 2 sessions per week
Exclusion Criteria:
* Patient who has already undergone speech therapy rehabilitation as part of their hearing loss treatment
* Diagnosis of neurodegenerative disease or history of brain injury (traumatic brain injury, stroke, tumor, meningitis, etc.)
* Uncorrected vision or visual impairment affecting lip reading (e.g. AMD, glaucoma, unoperated cataract, etc.)
* Presence of severe tinnitus (score \> 56) on the Tinnitus Handicap Inventory (THI) questionnaire
* Significant cognitive impairment (CODEX C or D) or Montreal Cognitive Assessment (MOCA) score \< 23
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Repetition score, in words (with and without labial doppelganger) of Lafon's cochlear lists presented on video support in visual-only modality
Timeframe: 26 sessions (4,5 months)
2
Repetition score, in visemes (with and without labial doppelganger) of Lafon's cochlear lists presented on video support in visual-only modality